MESO - Mesoblast: Rolling The Dice On Cellular Medicines

2024-07-22 01:50:46 ET

Summary

• Mesoblast is developing two key cellular medicines: rexlemestrocel-L and remestemcel-L, targeting serious diseases.
• Rexlemestrocel-L is in Phase 3 trials for heart failure and chronic back pain but faces inconsistency in efficacy data.
• Remestemcel-L's approval for SR-aGVHD has been denied twice, with a third submission currently pending.
• Despite interesting technology, Mesoblast's high operational and financial risks outweigh potential returns, leading to a "Sell" recommendation.

Mesoblast: Navigating Regulatory Hurdles with Cellular Innovations

Mesoblast ( MESO ) (MEOBF) is an Australia-based biotechnology company committed to "bringing to market innovative cellular medicines to treat serious and life-threatening diseases with significant, unmet medical needs."...

For further details see: